The exploration on neoadjuvant chemoradiation for the treatment of rectal cancer

doi:10.3877/cma.j.issn.2095-3224.2016.04.013

Abstract

Abstract:

Neoadjuvant radiotherapy or chemoradiotherapy combined with total mesorectal excision (TME) surgery have been recommend for local advanced rectal cancer in NCCN/ESMO guidelines, Because those treatments have improved the outcomes for local advanced rectal cancer patients. In order to decrease the distant metastasis and increase the survival rate for those patients, there are more and more researches which arranged the radiotherapy and chemotherapy in different ways. What is so exciting is that the preliminary result is quite well.

Key words: Rectal neoplasms, Therapy, Antineoplastic combined chemotherapy protocols, Radiotherapy, computer-assisted

Shuai Li, Jing Jin. The exploration on neoadjuvant chemoradiation for the treatment of rectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 05(04): 341-343.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2016.04.013

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2016/V05/I04/341

Figures/Tables 1

References 13

[1]	Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage Ⅱ or Ⅲ colon cancer in the MOSAIC trial[J]. J Clin Oncol, 2009, 27(19):3109-3116.
[2]	Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage Ⅲ colon cancer[J]. J Clin Oncol, 2011, 29(11):1465-1471.
[3]	Yothers G, O′Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses[J]. J Clin Oncol, 2011, 29(28):3768-3774.
[4]	Breugom AJ, Swets M, Bosset JF, et al. Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data[J]. Lancet Oncol, 2015, 16(2):200-207.
[5]	Borowski DW, Bradburn DM, Mills SJ, et al. Northern Region Colorectal Cancer Audit G: Volume-outcome analysis of colorectal cancer-related outcomes. Br J Surg, 2010, 97(9):1416-1430.
[6]	Paun BC, Cassie S, MacLean AR, et al. Postoperative complications following surgery for rectal cancer[J]. Ann Surg, 2010, 251(5):807-818.
[7]	Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase Ⅱ randomized trialdagger[J]. Ann Oncol, 2015, 26(8):1722-1728.
[8]	Fernandez-Martos C, Pericay C, Aparicio J, et al. Phase Ⅱ, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study[J]. J Clin Oncol, 2010, 28(5):859-865.
[9]	Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial[J]. J Clin Oncol, 1999, 17(8):2396.
[10]	Glehen O, Chapet O, Adham M, et al. Long-term results of the Lyons R90-01 randomized trial of preoperative radiotherapy with delayed surgery and its effect on sphincter-saving surgery in rectal cancer[J]. Br J Surg, 2003, 90(8):996-998.
[11]	Sloothaak DA, Geijsen DE, van Leersum NJ, et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer[J]. Br J Surg, 2013, 100(7):933-939.
[12]	Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial[J]. Lancet Oncol, 2015, 16(8):957-966.
[13]	Nilsson PJ, van Etten B, Hospers GA, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial[J]. BMC Cancer, 2013, 13:279.

研究类型	发起人	拟病例数	拟研究时间	拟研究方案	研究终点
Ⅱ期随机对照研究	Harbin Medical University	80	2013.7 -2018.1	a.同步放化疗 b.化疗＋同步放化疗＋化疗	3年DFS 3年复发率R0切除率pCR
Ⅱ/Ⅲ期随机对照研究	National Cancer Institute （NCI）	1060	2012.1 -2017.7	a.诱导化疗±放化疗＋手术＋化疗 b.同步放化疗＋手术＋化疗	Ⅱ：R0 / Ⅲ：DFS pCR、OS、AE
Ⅱ期随机对照研究	Grupo Espanol Multidisciplinario del Cancer Digestivo	180	2015.1 -2020.3	a.新辅助化疗和Aflibercept＋同步放化疗＋手术 b.新辅助化疗＋同步放化疗＋手术	pCR R0切除率、术后并发症3年DFS复发率
Ⅱ期单臂研究	中山大学	84	2014.8 -2017.8	FOLFOXIRI（4Cycle）＋TME	术后病理Stage0/I
Ⅱ期单臂研究	意大利	50	2013.7 -2018.7	FOLFOX4＋Tomo放疗＋FOLFOX4＋TME＋FOLFOX	治疗毒性、pCR
Ⅱ期单臂研究	中山大学	45	2013.3 -2020.3	XELOX和贝伐＋贝伐和XELOX同步放化疗＋TME手术	TRG分级5年OS治疗毒性
Ⅲ期随机对照研究	中山大学	556	2014.1 -2023.1	a.标准术前同步放化疗 b.诱导化疗＋放化疗＋间歇化疗	5年OS/DFS肿瘤降期率
Ⅲ期随机对照研究	UNICANCER	460	2012.1 -2022.1	a.同步放化疗＋手术 b.新辅助化疗＋同步放化疗＋手术	3年DFS 7年OS
Ⅲ期随机对照研究	中山大学	648	2014.8 -2024.6	a.新辅助化疗＋手术＋化疗 b.同步放化疗＋手术＋化疗	5年局部复发率5年DFS/OS、pCR
Ⅲ期随机对照研究	美国MSKCC	222	2013.11 -2017.11	a.新辅助化疗＋同步放化疗 b.同步放化疗＋新辅助化疗	3年DFS治疗毒副反应
Ⅲ期随机对照研究	波兰RAPIDO	885	2011.6 -2019.6	a. 5X5＋XELOX＋手术 b.同步放化疗＋手术	3年DFS 5年OS、pCR CRM阴性率
Ⅲ期随机对照研究	德国CAOAROAIO-12	304	2015.2 -2022.5	a.新辅助化疗＋同步放化疗 b.同步放化疗＋新辅助化疗	pCR术后并发症、降期率R0切除率、RFS、OS

研究类型	发起人	拟病例数	拟研究时间	拟研究方案	研究终点
Ⅱ期随机对照研究	Harbin Medical University	80	2013.7 -2018.1	a.同步放化疗 b.化疗＋同步放化疗＋化疗	3年DFS 3年复发率R0切除率pCR
Ⅱ/Ⅲ期随机对照研究	National Cancer Institute （NCI）	1060	2012.1 -2017.7	a.诱导化疗±放化疗＋手术＋化疗 b.同步放化疗＋手术＋化疗	Ⅱ：R0 / Ⅲ：DFS pCR、OS、AE
Ⅱ期随机对照研究	Grupo Espanol Multidisciplinario del Cancer Digestivo	180	2015.1 -2020.3	a.新辅助化疗和Aflibercept＋同步放化疗＋手术 b.新辅助化疗＋同步放化疗＋手术	pCR R0切除率、术后并发症3年DFS复发率
Ⅱ期单臂研究	中山大学	84	2014.8 -2017.8	FOLFOXIRI（4Cycle）＋TME	术后病理Stage0/I
Ⅱ期单臂研究	意大利	50	2013.7 -2018.7	FOLFOX4＋Tomo放疗＋FOLFOX4＋TME＋FOLFOX	治疗毒性、pCR
Ⅱ期单臂研究	中山大学	45	2013.3 -2020.3	XELOX和贝伐＋贝伐和XELOX同步放化疗＋TME手术	TRG分级5年OS治疗毒性
Ⅲ期随机对照研究	中山大学	556	2014.1 -2023.1	a.标准术前同步放化疗 b.诱导化疗＋放化疗＋间歇化疗	5年OS/DFS肿瘤降期率
Ⅲ期随机对照研究	UNICANCER	460	2012.1 -2022.1	a.同步放化疗＋手术 b.新辅助化疗＋同步放化疗＋手术	3年DFS 7年OS
Ⅲ期随机对照研究	中山大学	648	2014.8 -2024.6	a.新辅助化疗＋手术＋化疗 b.同步放化疗＋手术＋化疗	5年局部复发率5年DFS/OS、pCR
Ⅲ期随机对照研究	美国MSKCC	222	2013.11 -2017.11	a.新辅助化疗＋同步放化疗 b.同步放化疗＋新辅助化疗	3年DFS治疗毒副反应
Ⅲ期随机对照研究	波兰RAPIDO	885	2011.6 -2019.6	a. 5X5＋XELOX＋手术 b.同步放化疗＋手术	3年DFS 5年OS、pCR CRM阴性率
Ⅲ期随机对照研究	德国CAOAROAIO-12	304	2015.2 -2022.5	a.新辅助化疗＋同步放化疗 b.同步放化疗＋新辅助化疗	pCR术后并发症、降期率R0切除率、RFS、OS

[1]	The Joint Surgery Branch of the Chinese Orthopedic Association, Guangdong’s Medical Association of Osteoporosis And Bone Mineral Research, Foshan Shunde 3rd Peoele’s Hospital. Clinical intervention guideline for using of anti-osteoporosis drugs in postoperative fragile hip fractures in China (2023 Edition) [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 751-764.
[2]	Xu Tang, Bing Han, Wei Liu, Ruxing Chen. Analysis of risk factors for metachronous liver metastases after radical colorectal cancer surgery and construction of a predictive model [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 16-20.
[3]	Shengjun Zhang, Ajing Zhao, Shoubo Li, Xianghong Hao, Minli Liu. An experimental study on the promotion of colorectal cancer invasion and migration by high glucose through HGF/c-met pathway [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 21-24.
[4]	Yanhui Zhang, Jiao Zhang, Zhixian Zhu. Effect of indwelling anal tube on anastomotic leakage after laparoscopic total mesangectomy after neoadjuvant chemoradiotherapy in patients with middle and low rectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 25-28.
[5]	Ting Li, Lin Zhang. Relationship between serum fatty acid metabolites and vitamin D levels and colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 661-665.
[6]	Zhenbao Fu, Wanlong Cao, Fuhong Liu. Clinical effect of double ileal stomy with different suture methods during laparoscopic low anterior resection of rectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 684-687.
[7]	Zhibo Gu, lin Hao, Ming Lu, Jiangang Chen. Photodynamic nanocarriers combined with siP3H4 for precise targeting therapy in the treatment of bladder cancer: a pilot study [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(06): 633-641.
[8]	Bo Kong, Jing Zhang, Ke Lyu. Review on the role of ultrasonography in the diagnosis and treatment of complex ventral hernia [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(06): 670-673.
[9]	Guangjun Zhong, Chunhua Liu, Wansen Zhu, Xiaolei Xu, Zhaojun Wang. Application of conventional MRI combined with different scanning sequences in preoperative staging diagnosis, chemotherapy efficacy and prognosis evaluation of gastric cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 378-382.
[10]	Qiujie Shan, Lizhu Sun, Yiquan Xu, Zhixia Wang, Yan Xu, Hao Ma, Tiantian Liu. Construction and application of radiation-induced lung injury risk model for middle-aged and elderly patients with esophageal cancer during intensity modulated radiotherapy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 388-393.
[11]	Baoru Hu, Naijian Shang, Di Gao. DCE-MRI and DWI findings of advanced hepatocellular carcinoma and their correlation with prognosis after immunotherapy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 399-403.
[12]	Xiankui Gao, Taiyun Zhao, Xingjun Lu, Hongling Zhang, Xiuluo Fang, Bichun Yan, Yin Wang, Yongcui Wang, Miaomiao Liu, Ruonan Ran. Efficacy of endoscopic electrocoagulation and tissue glue injection in the treatment of upper gastrointestinal ulcer with bleeding [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 452-455.
[13]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[14]	Yingqian Li, Huashan Li. Evaluation of treatment methods for complete rectal prolapse: a real world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 700-705.
[15]	Meisha Fu, Yuhua Zhou, Hui Li, Chunyan Xue. Effect of lymphocyte immunotherapy on T lymphocyte subset distribution and PD1/PD-L1 expression in patients with recurrent miscarriage [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 726-730.

Please choose a citation manager

Content to export